Portfolio

CARDIOR

Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept (POC) data.

Pressemeldungen

Cardior Pharmaceuticals raises €15 million to develop first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure

Cardior Pharmaceuticals, a spin-off from Hannover Medical School (MHH), today announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its…
Read

Info & Contact

Dr. Claudia Ulbrich
Web:
www.cardior.de

Address

Cardior Pharmaceuticals GmbH
Carl-Neuberg-Str. 1
30625 Hannover

In portfolio

03. May 2017